
Annual report 2021
added 12-23-2023
Burning Rock Biotech Limited Retained Earnings 2011-2026 | BNR
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.23 B | -1.42 B | -946 M | -612 M | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -612 M | -2.23 B | -1.3 B |
Quarterly Retained Earnings Burning Rock Biotech Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -2.23 B | - | - | - | -1.42 B | - | - | - | -946 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -946 M | -2.23 B | -1.53 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
348 M | $ 115.62 | 0.06 % | $ 35.1 B | ||
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
-80.4 M | $ 1.65 | -1.2 % | $ 2.19 M | ||
|
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
-200 M | $ 24.98 | 2.13 % | $ 694 M | ||
|
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M | ||
|
CareDx, Inc
CDNA
|
-735 M | $ 21.85 | 2.92 % | $ 1.16 B | ||
|
Illumina
ILMN
|
-1.24 B | $ 128.52 | 0.5 % | $ 20.4 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
590 M | $ 15.6 | -4.35 % | $ 472 M | ||
|
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | ||
|
Lantheus Holdings
LNTH
|
680 M | $ 84.11 | -0.26 % | $ 5.68 B | ||
|
Charles River Laboratories International
CRL
|
1.39 B | $ 171.23 | 0.86 % | $ 8.49 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
-460 M | $ 421.37 | 2.64 % | $ 12.2 B | ||
|
Guardant Health
GH
|
-2.99 B | $ 88.5 | -0.46 % | $ 11.1 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | ||
|
Personalis
PSNL
|
-550 M | $ 5.96 | -2.3 % | $ 353 M | ||
|
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
-211 M | $ 1.93 | -2.08 % | $ 8.54 M | ||
|
Senseonics Holdings
SENS
|
-1.02 B | $ 7.27 | 3.12 % | $ 303 M | ||
|
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | ||
|
Soleno Therapeutics
SLNO
|
-431 M | $ 52.75 | 0.06 % | $ 2.68 B | ||
|
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B | ||
|
Neogen Corporation
NEOG
|
-536 M | $ 9.45 | -0.94 % | $ 2.05 B | ||
|
Biomerica
BMRA
|
-53.2 M | $ 2.18 | 1.87 % | $ 5.01 M | ||
|
National Research Corporation
NRC
|
-17.3 M | $ 17.11 | -0.7 % | $ 383 M | ||
|
Thermo Fisher Scientific
TMO
|
59.2 B | $ 468.04 | -0.36 % | $ 176 B | ||
|
ICON Public Limited Company
ICLR
|
2.72 B | $ 103.21 | 1.02 % | $ 8.51 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 263.43 | -0.12 % | $ 21.9 B | ||
|
Trinity Biotech plc
TRIB
|
10.6 M | $ 0.64 | -0.82 % | $ 61.9 M | ||
|
Celcuity
CELC
|
-449 M | $ 125.68 | 3.84 % | $ 5.88 B | ||
|
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 61.0 | 0.1 % | $ 3.65 B | ||
|
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | ||
|
NeoGenomics
NEO
|
-434 M | $ 8.61 | 3.86 % | $ 1.1 B | ||
|
Myriad Genetics
MYGN
|
-1.12 B | $ 4.83 | 1.05 % | $ 447 M | ||
|
Natera
NTRA
|
-1.94 B | $ 204.39 | 0.31 % | $ 20.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 196.63 | 0.21 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M |